publication . Other literature type . Article . 2019

A meta-analysis of anti-interleukin-13 monoclonal antibodies for uncontrolled asthma

Hang Li; Kai Wang; Huiting Huang; Wenbin Cheng; Xiaohong Liu;
  • Published: 31 Jan 2019
  • Publisher: Public Library of Science (PLoS)
Abstract
More and more clinical trials have tried to assess the clinical benefit of anti-interleukin (IL)-13 monoclonal antibodies for uncontrolled asthma. The aim of this study is to evaluate the efficacy and safety of anti-IL-13 monoclonal antibodies for uncontrolled asthma. Major databases were searched for randomized controlled trials comparing the anti-IL-13 treatment and a placebo in uncontrolled asthma. Outcomes, including asthma exacerbation rate, forced expiratory volume in 1 second (FEV1), Asthma Quality of Life Questionnaire (AQLQ) scores, rescue medication use, and adverse events were extracted from included studies for systematic review and meta-analysis. Fi...
Subjects
free text keywords: Research Article, Medicine and Health Sciences, Pulmonology, Asthma, Research and Analysis Methods, Research Design, Clinical Research Design, Adverse Events, Biology and Life Sciences, Physiology, Immune Physiology, Antibodies, Monoclonal Antibodies, Immunology, Immune System Proteins, Biochemistry, Proteins, Clinical Medicine, Clinical Trials, Randomized Controlled Trials, Pharmacology, Drug Research and Development, Mathematical and Statistical Techniques, Statistical Methods, Metaanalysis, Physical Sciences, Mathematics, Statistics, Research Assessment, Systematic Reviews, Immune Response, Inflammation, Diagnostic Medicine, Signs and Symptoms, Pathology and Laboratory Medicine, Database and Informatics Methods, Database Searching, Medicine, R, Science, Q, General Biochemistry, Genetics and Molecular Biology, General Agricultural and Biological Sciences, General Medicine, Randomized controlled trial, law.invention, law, Lebrikizumab, medicine.drug, Clinical trial, Placebo, Subgroup analysis, Adverse effect, Tralokinumab, business.industry, business, medicine.disease, Internal medicine, medicine.medical_specialty
Related Organizations
Download fromView all 4 versions
PLoS ONE
Article . 2019
PLoS ONE
Article . 2019
Provider: Crossref
PLoS ONE
Article
Provider: UnpayWall
35 references, page 1 of 3

1 Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. American journal of respiratory and critical care medicine. 2004;170(8):836–44. 10.1164/rccm.200401-033OC 15256389 [OpenAIRE] [PubMed] [DOI]

2 Demoly P, Paggiaro P, Plaza V, Bolge S, Kannan H, Sohier B, et al Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. European Respiratory Review. 2009;18(112):105–12. 10.1183/09059180.00001209 20956130 [OpenAIRE] [PubMed] [DOI]

3 McCoy K, Shade DM, Irvin CG, Mastronarde JG, Hanania NA, Castro M, et al Predicting episodes of poor asthma control in treated patients with asthma. Journal of Allergy and Clinical Immunology. 2006;118(6):1226–33. 10.1016/j.jaci.2006.09.006 17157651 [OpenAIRE] [PubMed] [DOI]

4 Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. Journal of Allergy and Clinical Immunology. 2012;129(5):1229–35. 10.1016/j.jaci.2012.01.039 22326484 [OpenAIRE] [PubMed] [DOI]

5 Lai T, Wang S, Xu Z, Zhang C, Zhao Y, Hu Y, et al Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Scientific reports. 2015;5.

6 Cabon Y, Molinari N, Marin G, Vachier I, Gamez AS, Chanez P, et al Comparison of anti‐interleukin‐5 therapies in patients with severe asthma: global and indirect meta‐analyses of randomized placebo‐controlled trials. Clinical & Experimental Allergy. 2017;47(1):129–38.27859832 [OpenAIRE] [PubMed]

7 Hambly N, Nair P. Monoclonal antibodies for the treatment of refractory asthma. Current opinion in pulmonary medicine. 2014;20(1):87–94. 10.1097/MCP.0000000000000007 24275927 [PubMed] [DOI]

8 Huang S-K, Xiao H-Q, Kleine-Tebbe J, Paciotti G, Marsh DG, Lichtenstein LM, et al IL-13 expression at the sites of allergen cha llenge in patients with asthma. The Journal of Immunology. 1995;155(5):2688–94. 7650396 [PubMed]

9 Richter A, Puddicombe SM, Lordan JL, Bucchieri F, Wilson SJ, Djukanovic R, et al The contribution of interleukin (IL)-4 and IL-13 to the epithelial–mesenchymal trophic unit in asthma. American Journal of Respiratory Cell and Molecular Biology. 2001;25(3):385–91. 10.1165/ajrcmb.25.3.4437 11588018 [OpenAIRE] [PubMed] [DOI]

10 Kondo M, Tamaoki J, Takeyama K, Isono K, Kawatani K, Izumo T, et al Elimination of IL-13 Reverses Established Goblet Cell Metaplasia into Ciliated Epithelia in Airway Epithelial Cell Culture. Allergology Inte rnational. 2006;55(3):329–36. 10.2332/allergolint.55.329 17075276 [OpenAIRE] [PubMed] [DOI]

11 Luttmann W, Knoechel B, Foerster M, Matthys H, Virchow J, Kroegel C. Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. The Journal of Immunology. 1996;157(4):1678–83. 8759755 [PubMed]

12 Hua F, Ribbing J, Reinisch W, Cataldi F, Martin S. A pharmacokinetic comparison of anrukinzumab, an anti‐IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. British journal of clinical pharmacology. 2015;80(1):101–9. 10.1111/bcp.12589 25614144 [OpenAIRE] [PubMed] [DOI]

13 Oh CK, Faggioni R, Jin F, Roskos LK, Wang B, Birrell C, et al An open‐label, single‐dose bioavailability study of the pharmacokinetics of CAT‐354 after subcutaneous and intravenous administration in healthy males. British journal of clinical pharmacology. 2010;69(6):645–55. 10.1111/j.1365-2125.2010.03647.x 20565456 [OpenAIRE] [PubMed] [DOI]

14 Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R, et al Increased sputum and bronchial biopsy IL-13 expression in severe asthma. Journal of Allergy and Clinical Immunology. 2008;121(3):685–91. 10.1016/j.jaci.2008.01.005 18328894 [OpenAIRE] [PubMed] [DOI]

15 Grünig G, Corry DB, Reibman J, Wills-Karp M. Interleukin 13 and the evolution of asthma therapy. American journal of clinical and experimental immunology. 2012;1(1):20 23607082 [OpenAIRE] [PubMed]

35 references, page 1 of 3
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue